Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD209 | Q9NNX6 | 2/20 | 0.49 |
| ▸ | ENGASE | Q8NFI3 | 1/20 | 0.47 |
| ▸ | LGALS8 | O00214 | 3/20 | 0.40 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.40 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.40 |
| ▸ | FGF1 | P05230 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | G6PD | P11413 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.37 |
| ▸ | AMY2A | P04746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16853902 | 0.95 | CD209 (0.56) | CD209ENGASELGALS8LGALS3LGALS4 | |
| SCHEMBL16850464 | 0.95 | CD209 (0.56) | CD209ENGASELGALS8LGALS3LGALS4 | |
| SCHEMBL17831221 | 0.92 | CD209 (0.54) | CD209ENGASELGALS8LGALS3LGALS4 | |
| SCHEMBL5525028 | 0.90 | CD209 (0.60) | CD209ENGASELGALS8LGALS3LGALS4 | |
| SCHEMBL13290316 | 0.90 | CD209 (0.60) | CD209ENGASELGALS8LGALS3LGALS4 | |
| SCHEMBL11220673 | 0.90 | CD209 (0.60) | CD209ENGASELGALS8LGALS3LGALS4 | |
| SCHEMBL6815714 | 0.90 | CD209 (0.60) | CD209ENGASELGALS8LGALS3LGALS4 | |
| SCHEMBL14227992 | 0.90 | CD209 (0.60) | CD209ENGASELGALS8LGALS3LGALS4 | |
| SCHEMBL17830236 | 0.90 | CD209 (0.60) | CD209ENGASELGALS8LGALS3LGALS4 | |
| SCHEMBL11220668 | 0.90 | CD209 (0.60) | CD209ENGASELGALS8LGALS3LGALS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238325-A1 | Artificial Nucleic Acid and Method for Delivery of Nucleic Acid Using the Same | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240238325-A1 | Artificial Nucleic Acid and Method for Delivery of Nucleic Acid Using the Same | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238325-A1 | Artificial Nucleic Acid and Method for Delivery of Nucleic Acid Using the Same | HNRNPH3, RNASEH1, HNRNPA1 | CD209 2162/4885ENGASE 2714/4885LGALS8 2258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.